Skip to main content

Biohaven Ltd.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

BHVN$15.11-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Operating expenses:
Research and development$100,814$184,367$204,641$371,951
General and administrative24,08527,33450,68661,311
Total operating expenses124,899211,701255,327433,262
Loss from operations(124,899)(211,701)(255,327)(433,262)
Other (expense) income, net(12,021)13,815(11,853)14,308
Loss before provision for income taxes(136,920)(197,886)(267,180)(418,954)
Provision for income taxes391261663870
Net loss$(137,311)$(198,147)$(267,843)$(419,824)
Net loss per share — basic and diluted$(0.91)$(1.94)$(1.80)$(4.11)
Weighted average common shares outstanding—basic and diluted150,636,620102,372,820149,134,255102,159,294
Comprehensive loss:
Net loss$(137,311)$(198,147)$(267,843)$(419,824)
Other comprehensive loss, net of tax(2,927)(76)(2,973)(82)
Comprehensive loss$(140,238)$(198,223)$(270,816)$(419,906)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.